Zacks Research Has Pessimistic Outlook of CRL Q1 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Stock analysts at Zacks Research cut their Q1 2025 earnings per share estimates for shares of Charles River Laboratories International in a research report issued to clients and investors on Wednesday, March 12th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $2.08 per share for the quarter, down from their previous estimate of $3.10. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q2 2025 earnings at $2.38 EPS, Q3 2025 earnings at $2.51 EPS, Q4 2025 earnings at $2.58 EPS, FY2025 earnings at $9.55 EPS, Q1 2026 earnings at $2.46 EPS, Q2 2026 earnings at $2.66 EPS, Q3 2026 earnings at $2.71 EPS, Q4 2026 earnings at $2.78 EPS and FY2026 earnings at $10.60 EPS.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the previous year, the company posted $2.46 EPS. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year.

Other equities research analysts also recently issued research reports about the company. JPMorgan Chase & Co. dropped their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. The Goldman Sachs Group dropped their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Barclays dropped their target price on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. Bank of America dropped their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, Robert W. Baird dropped their target price on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $198.36.

Charles River Laboratories International Trading Up 2.3 %

CRL stock opened at $175.02 on Monday. The company has a market cap of $8.95 billion, a P/E ratio of 1,166.77, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $274.77. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The business has a fifty day moving average of $167.46 and a 200-day moving average of $184.33.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Charles River Laboratories International by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock worth $1,136,938,000 after acquiring an additional 60,497 shares in the last quarter. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after acquiring an additional 335,658 shares in the last quarter. State Street Corp raised its holdings in Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after acquiring an additional 47,221 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Charles River Laboratories International by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock valued at $227,042,000 after buying an additional 14,787 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).